Immune cells take on tough leukemia in early trial
NCT ID NCT05987696
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new treatment using lab-grown immune cells (iPSC NK cells) in 2 adults with hard-to-treat acute myeloid leukemia (AML) or signs of remaining disease after treatment. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the cells were fighting the leukemia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can targeted drug cocktails erase hidden leukemia cells?
- Blood test may end painful bone marrow biopsies for myeloma patients
- Engineered immune cells take aim at tough childhood leukemia
- Can a simple blood test tell who needs more cancer treatment?
- Can a simple blood test tell if cancer is really gone?
- Could early comfort care change End-of-Life for blood cancer patients?